乐普生物-B（02157）今日盘中大涨24.23%，引发市场广泛关注。截至发稿，该股涨幅达22.7%，报4港元，成交额1.2亿港元。
公司最新发布的年度业绩报告显示，全年收入达3.68亿元人民币，同比增长63.21%。收入增长主要来自三个方面：普佑恒（普特利单抗注射液）销售收入达3亿元，较去年增长近3倍；CMG901项目里程碑付款及技术转让服务的对外授权收入2200万元；以及CDMO服务收入4550万元。值得注意的是，公司拥有人应占亏损为4.11亿元，同比扩大1761.77%。
此外，乐普生物宣布，其自主研发的候选药物MRG003（一种EGFR靶向抗体药物偶联物，用于治疗复发性或转移性鼻咽癌）的关键注册性IIb期研究结果入选2025年美国临床肿瘤学会（ASCO）年会"重磅研究摘要"，并将在会上进行口头报告。这一消息进一步提振了投资者对公司研发实力和未来发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.